MediWound, 3M to collaborate
By HME News Staff
Updated 8:44 AM CDT, Thu October 12, 2023
YAVNE, Israel – 3M Health Care will provide its two-layer compression systems, Coban 2 and Coban 2 Lite, to be used during the debridement and wound healing phases of the EscharEx Phase III study as part of a collaboration with MediWound, a biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair. "In our pursuit of excellence, one primary aim is to ensure consistency across subjects while delivering optimal care throughout the study,” said Ofer Gonen, CEO, MediWound. “3M Health Care's Coban compression systems stand out as global market leaders, and we're pleased to designate them as the standard for our Phase 3 study. Given that compression therapy is pivotal in managing venous leg ulcers (VLUs), it's imperative that we employ top-tier products. With 3M Health Care’s two-layer compression systems, we're confident we're doing just that." EscharEx is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During the debridement phase, as well as in the wound healing phase of the study, 3M’s two-layer compression systems will be used as standard of care in all study arms, until the wounds reach complete healing.
Comments